Exploring Safety of Higher Doses of Primaquine: Advancing Towards Vivax Elimination| APMEN TechTalks

In 2022, during an extensive prioritisation exercise with National Malaria Programmes in the Asia Pacific region, the APMEN Vivax Working Group found that NMPs wanted to better understand the safety of shorter course primaquine for vivax malaria. This reflects the latest WHO recommendations which identified an evidence gap on the safety of shorter course primaquine. Studies and analyses are underway to try to bridge this gap. This TechTalks webinar discussed recent research and meta-analyses on primaquine safety and identify what additional evidence is required.